Mineralys Therapeutics, Inc. filed a Form 8-K on August 11, 2026, disclosing the appointment of a new Chief Medical Officer effective August 10, 2026, and announcing financial results for the quarter ended June 30, 2026.

Key Highlights

  • New CMO appointed: James J. Ferguson III, M.D., was appointed Chief Medical Officer by the Board of Directors on August 5, 2026, effective August 10, 2026.
  • Prior CMO transitions to Strategic Advisor: David Rodman, M.D., remains with the company on a full-time basis in a Strategic Advisor role, effective August 10, 2026.
  • Officer status change: The Board determined, following a detailed review, that Dr. Rodman no longer satisfies the definition of "officer" under Rule 16a-1(f) or "executive officer" under Rule 3b-7 of the Exchange Act.
  • Employment agreement amended: Dr. Rodman entered into an amendment to his Amended and Restated Employment Letter Agreement on August 5, 2026, to reflect his new role.
  • Quarterly results announced: A press release disclosing financial results for the quarter ended June 30, 2026, was issued on August 11, 2026, and attached as Exhibit 99.1.

Mineralys Therapeutics CMO Transition and Q2 2026 Results Announcement

According to the filing, Mineralys Therapeutics, Inc. (NASDAQ:MLYS) reported two distinct developments in its August 11, 2026 Form 8-K. The first concerns a leadership change at the Chief Medical Officer level. The Board of Directors appointed James J. Ferguson III, M.D., as Chief Medical Officer on August 5, 2026, with the appointment taking effect August 10, 2026.

The filing states that David Rodman, M.D., who previously served as Chief Medical Officer, will remain with the company on a full-time basis as a Strategic Advisor. The Board disclosed that it "completed a detailed review of Dr. Rodman's new functions and responsibilities" and determined he no longer meets the definitions of "officer" under Rule 16a-1(f) or "executive officer" under Rule 3b-7 of the Exchange Act. In connection with this transition, Dr. Rodman entered into an amendment to his Amended and Restated Employment Letter Agreement on August 5, 2026, effective August 10, 2026. The filing notes that the description of the amendment "is not complete and is qualified in its entirety by reference to the full text of the Amendment," attached as Exhibit 10.1.

The second item disclosed under Item 2.02 concerns financial results. The company issued a press release on August 11, 2026, announcing results for the quarter ended June 30, 2026, and providing a corporate update. That press release is incorporated by reference as Exhibit 99.1. The filing notes that the information furnished under Item 2.02, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. The registrant is identified as an emerging growth company.

What Was Disclosed

Mineralys Therapeutics disclosed the appointment of James J. Ferguson III, M.D., as Chief Medical Officer effective August 10, 2026, the transition of David Rodman, M.D., to a Strategic Advisor role, and the release of second-quarter 2026 financial results.